NWBO - Northwest Bio plunges after late-stage data for lead candidate in brain cancer

The shares of Northwest Biotherapeutics (OTCQB:NWBO) reached a 52-week low on Tuesday after the clinical-stage immunotherapy company announced a presentation with Phase 3 data for its lead asset DCVax-L in Glioblastoma multiforme (GBM) brain cancer. Northwest (OTCQB:NWBO) develops product candidates based on its DCVax platform which is designed to utilize the activated dendritic cells to induce a patient’s immune system to attack cancer. The presentation was made by Dr. Paul Mulholland of University College Hospital at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences today. According to overall results, the 331-patient trial has met the primary endpoint of overall survival (OS) in newly diagnosed GBM patients. OS is the “gold standard” for measuring the clinical benefits of a cancer drug. The progression free survival (PFS) the initial primary endpoint of the trial, was found to be unviable. The global trial has also reached the secondary

For further details see:

Northwest Bio plunges after late-stage data for lead candidate in brain cancer